Clinical Trials Logo

Lactation Suppressed clinical trials

View clinical trials related to Lactation Suppressed.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT06029673 Enrolling by invitation - Clinical trials for Lactation Suppressed

Cabergoline for Lactation Inhibition After Early Second-Trimester Abortion or Pregnancy Loss

eLISTA
Start date: February 7, 2024
Phase: Phase 2
Study type: Interventional

Breast pain following second-trimester abortion is common. Breast engorgement and milk leakage following second-trimester perinatal loss and abortion can cause both physical pain and emotional distress. Dopamine agonists have previously been shown to be effective in lactation inhibition for third-trimester fetal/neonatal loss or contraindications to breastfeeding. The investigator's prior work demonstrated that compared to placebo, a single dose of cabergoline was effective in preventing breast symptoms after abortion or loss 18-28 weeks. As lactogenesis starts as early as 16 weeks gestation, the investigators hope to determine the efficacy of cabergoline earlier in the second trimester,16-20 weeks.